SecBot SecBot
PRESS-RELEASE ·Filed Mar 16, 2026

OLMA

Olema Oncology
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor upcoming clinical catalysts, OP-3136 data in Q2 2026 and OPERA-01 top-line readout in fall 2026, as key value inflection points. The strengthened balance sheet supports operations into 2027, reducing near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.60
T+0 close · Mar 16, 2026 · via day close
Latest settled
−40.00%
T+60 · $9.96
Vs SPY
−50.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $16.60entry
  2. T+1 · 8mo ago −9.31%α −9.58% · $15.06
  3. T+5 · 8mo ago −15.84%α −13.80% · $13.97
  4. T+20 · 7mo ago −1.81%α −5.59% · $16.30
  5. T+60 · 5mo ago −40.00%α −50.48% · $9.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Olema Oncology reported financial results for 2025, showing increased net losses due to higher R&D spending on late-stage trials for palazestrant and early development of OP-3136. The company raised $218.5 million in a follow-on offering, ending the year with $505.4 million in cash. Key catalysts ahead include top-line data from the Phase 3 OPERA-01 trial in fall 2026 and initial clinical results for OP-3136 in Q2 2026.

Key Financial Metrics

EPS
$-1.87

Key Facts

  • Net loss for 2025 was $162.5 million, up from $129.5 million in 2024, driven by increased R&D spending.
  • GAAP R&D expenses rose to $157.7 million in 2025 from $124.5 million in 2024, including a $10M milestone payment (vs. $5M in 2024).
  • Company raised $218.5 million in gross proceeds from a public offering, ending 2025 with $505.4 million in cash and marketable securities.
  • Top-line data from Phase 3 OPERA-01 trial expected in fall 2026; initial OP-3136 data expected Q2 2026.
  • No revenue generated; company remains pre-commercial with no product sales.

Financial Impact

Increased annual net loss by $33 million YoY; cash position increased by $71.3 million to $505.4 million after offering.

net losscashR&D expensedilution

Risk Factors

  • Clinical trial setbacks could materially impact valuation, as the company is entirely dependent on development-stage assets.
  • Continued losses and future capital raises may lead to shareholder dilution.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3256109

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 16, 2026